⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,114.23
−0.64%
Brent
$110.48
+1.15%
BTC
$81,306.58
−0.65%
ETH
$2,389.22
−0.66%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,114.23
−0.64%
Brent
$110.48
+1.15%
BTC
$81,306.58
−0.65%
ETH
$2,389.22
−0.66%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Eli Lilly and Co · News · TradingHolo
Markets
›
United States
› NYSE
› LLY
E
Eli Lilly and Co
NYSE:LLY
Healthcare
CBOE:SPESG
NASDAQ:NQUSLG
$1,240.34
−1.33%
At close
At close · Tue 20 Oct · ≈
AED 4,555.15
· Market cap
$1.17T
· Next earnings
Thu 29 Oct
· Extended
$1,256.51
+1.30%
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
LLY news
Headlines tagged to this company
DO
Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials With Ely Lilly
Dow Jones Newswires · 19 d ago
DO
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart — Barrons.com
Dow Jones Newswires · 19 d ago
SE
Lilly Foundayo is predicted to cut diabetes risk by 57% in late-stage study
Seeking Alpha · 19 d ago
RE
Eli Lilly - Foundayo 17.2 Mg Associated With 57% Reduction In Diabetes Risk, 18% In Cardiovascular Risk Versus Placebo
Reuters · 19 d ago
DO
The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind — WSJ
Dow Jones Newswires · 20 d ago
DO
Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial
Dow Jones Newswires · 20 d ago
RE
Lilly's Foundayo Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction And Weight Loss
Reuters · 20 d ago
GU
Eli Lilly Scores Major Win for Key Eczema Drug
GuruFocus · 20 d ago
RE
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Reuters · 20 d ago
SE
Pharmaceutical industry lobbying group names new CEO, Eric Cantor
Seeking Alpha · 20 d ago
SE
Lilly says Zepbound combo delivered superior weight loss in mid-stage trial
Seeking Alpha · 20 d ago
RE
Weight-loss drug developers line up to tap lucrative market as competition heats up
Reuters · 20 d ago
RE
Eli Lilly Plans To Initiate Phase 3 Studies Of Eloratzp Co-Formulation Product By 2026 End
Reuters · 20 d ago
TR
Eli Lilly and Company (LLY) Combo Exceeds Tirzepatide on Weight and A1C
TradingView · 20 d ago
PR
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
PR Newswire · 20 d ago
DO
Lilly's Next-Gen Obesity Drug Helps People Lose Even More Weight in Study — WSJ
Dow Jones Newswires · 20 d ago
SE
Lilly posts late-stage trial win for Ebglyss in hand-and-foot atopic dermatitis
Seeking Alpha · 20 d ago
RE
Major drugmakers turn to China for licensing deals
Reuters · 20 d ago
← Previous
More news →